Retinol-binding Protein 4 (RBP4) Metabolizm in Type 2 Diabetes Progression and Associated Cardiovascular Complications

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04325126

Acronym

RMTACC

Enrollment

500

Registered

2020-03-27

Start date

2020-04-01

Completion date

2023-01-31

Last updated

2022-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

Retinol-binding protein 4 (RBP4) may affects obesity development and the development of obesity-related diseases including insulin resistance, type 2 diabetes, steatohepatitis and cardiovascular disease. This study aims to examine the involvement of RBP4 in patients with diagnosed diabetes, diabetic cardiovascular disease, pre-diabetes (pre-DM) and healthy controls during the progression of T2DM, and to evaluate the ability of RBP4 to predict cases of diabetes with an elevated risk of cardiovascular complications . Along with animal experiment.

Detailed description

A total of 500 Chinese patients admitted to the First Affliated Hospital of Xi'an Jiaotong University (Xi'an, China) between March 2020 and March 2022 were recruited to investigate the RBP4 profles. Peripheral blood samples are drawn at the initial medical examination, in the morning after a fast of at least 8 h, and immediately stored at -80˚C until the sphingolipid measurements were performed. Blood pressure, WC, hip circumference (HC), body weight and body height were measured by a trained physician. The participants enrolled in the study provided written informed consent.

Interventions

OTHERExposure factors

Exposure factors，such as diet，exercise，environment

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

T2DM: * Fasting plasma glucose (FPG)≥7.0 mmol/l; * 2 h plasma glucose (2hPG) ≥11.1 mmol/l; * glycated hemoglobin (HbA1c) level ≥6.5%; * random plasma glucose ≥11.1 mmol/l plus symptoms of hyperglycemia; * T2DM diagnosed previously. Pre-DM was defned as follows: * FPG ≥5.6-6.9 mmol/l * 2hPG 7.8-11.0 mmol/l * HbA1c 5.7-6.4%.

Exclusion criteria

* type 1 diabetes * liver or kidney disorders.

Design outcomes

Primary

Measure	Time frame	Description
serum RBP4 level	2022.3	serum RBP4 level in DM, pre-DM, CVD, DM-CVD and healthy controls.

Countries

China

Contacts

Primary ContactJing Sui, doctor

suijing1029@163.com0086-18991989230

Backup ContactJing Sui, doctor

suijing1029@163.com0086-029-85324771

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026